- Your Allergy Meds Come With Hazards: Be Aware
- Vaping Linked to Earlier Onset of Asthma
- FDA Approves New Drug for Deadly Lung Cancer
- U.S. Justice Department Moves to Reclassify Weed as Less Risky Drug
- Global Life Expectancy Could Rise By More Than 4 Years by 2050
- Most Cancer Treatments Near End of Life Are Useless: Study
- Brain’s ‘Food Smell’ Circuitry Might Drive Overeating
- The More Kids Use Social Media, The More They’re Likely to Vape
- Men Are More Debilitated by Diabetes Than Women
- Is Your Child Ready for Summer Sleepaway Camp?
New Device Treats Superficial Varicose Veins
The VenaSeal closure system has been approved by the U.S. Food and Drug Administration to treat superficial varicose veins in the leg that appear close to the skin and cause an unsightly and sometimes painful condition.
The product, administered by a trained professional, is designed to seal the affected veins, preventing the pooling of blood in these vessels. It was clinically evaluated in a study of more than 200 participants, comparing it to another treatment called radio-frequency ablation.
“The trials showed the device to be safe and effective for vein closure for the treatment of symptomatic superficial varicose veins of the legs,” the FDA said Friday in a news release.
The VenaSeal system should not be used in people with a known sensitivity to the system’s adhesive, or in those with inflamed veins due to blood clots or infection. The most common side effects included vein inflammation and burning and tingling in the treatment area, the agency said.
The VenaSeal system is manufactured by Covidien LLC, in Morrisville, N.C.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.